Bijan Keikhaei1, Homayon Yousefi2, Mohammad Bahadoram3. 1. Associate Professor, Department of Pediatrics Hematalogy Oncology, Health Research Institute, Research Centre of Thalassemia and Hemoglobinopathies, Ahvaz Jundishapur University of Medical Sciences , Ahvaz, Iran . 2. Assistant Professor, Department of Pediatrics Hematalogy Oncology, Health Research Institute, Research Centre of Thalassemia and Hemoglobinopathies, Ahvaz Jundishapur University of Medical Sciences , Ahvaz, Iran . 3. Medical Student, Research Committee & Social Determinant of Health Research Center, Ahvaz Jundishapur University of Medical Sciences , Ahvaz, Iran .
Abstract
INTRODUCTION: It is well known that hydroxyurea (HU) impacts on clinical and haematologic indices in thalassemia. We aimed to evaluate the effect of hydroxyurea on clinical and haematological improvement in children with thalassemia intermedia. MATERIALS AND METHODS: After the patients' enrollment in the study their data such as transfusion, hospitalization, spleen size, visit, total Hb, HbF levels, MCV and MCH were compared before and after treatment with HU 10 mg/kg/day/for one year. RESULTS: In patients with thalassemia intermedia, HU significantly diminished the rate of transfusion, hospitalization, spleen size and significantly increased Hb MCH, HbF and MCV. Moreover HU was well tolerated in our patients and we got no remarkable adverse effect. CONCLUSION: We divulged hydroxyurea 10 mg/kg/day during one year. This significantly increased HbF, total haemoglobin, MCV, MCH, without any remarkable adverse events.
INTRODUCTION: It is well known that hydroxyurea (HU) impacts on clinical and haematologic indices in thalassemia. We aimed to evaluate the effect of hydroxyurea on clinical and haematological improvement in children with thalassemia intermedia. MATERIALS AND METHODS: After the patients' enrollment in the study their data such as transfusion, hospitalization, spleen size, visit, total Hb, HbF levels, MCV and MCH were compared before and after treatment with HU 10 mg/kg/day/for one year. RESULTS: In patients with thalassemia intermedia, HU significantly diminished the rate of transfusion, hospitalization, spleen size and significantly increased Hb MCH, HbF and MCV. Moreover HU was well tolerated in our patients and we got no remarkable adverse effect. CONCLUSION: We divulged hydroxyurea 10 mg/kg/day during one year. This significantly increased HbF, total haemoglobin, MCV, MCH, without any remarkable adverse events.
Authors: Jeffrey D Lebensburger; Tamara I Pestina; Russell E Ware; Kelli L Boyd; Derek A Persons Journal: Haematologica Date: 2010-04-07 Impact factor: 9.941
Authors: Jodi B Segal; John J Strouse; Mary Catherine Beach; Carlton Haywood; Catherine Witkop; Haeseong Park; Renee F Wilson; Eric B Bass; Sophie Lanzkron Journal: Evid Rep Technol Assess (Full Rep) Date: 2008-03
Authors: Rayan Bou-Fakhredin; Lucia De Franceschi; Irene Motta; Maria Domenica Cappellini; Ali T Taher Journal: Pharmaceuticals (Basel) Date: 2022-06-16
Authors: Nur Atikah Zakaria; Md Asiful Islam; Wan Zaidah Abdullah; Rosnah Bahar; Abdul Aziz Mohamed Yusoff; Ridhwan Abdul Wahab; Shaharum Shamsuddin; Muhammad Farid Johan Journal: Biomolecules Date: 2021-05-18